DZ BANK AG advised the shareholders of Plasmid Factory in the transaction with ArchiMed

PlasmidFactory is a leading contract manufacturer and service provider for plasmid and minicircle DNA. PlasmidFactory develops and manufactures exceptionally pure, high-quality plasmids and minicircles which are used to modify genes and cells and to produce viral gene therapy vectors like AAV or LV as well as mRNA for combating everything from viruses like COVID-19 to seemingly intractable diseases like cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS including CAR-T cell applications.With the investment and support of ArchiMed, PlasmidFactory will now fund the construction of an even larger GMP (Good Manufacturing Practices) compliant facility. Through the transaction, the companies will combine ArchiMed’s financial power and international healthcare network with PlasmidFactory’s experience, know-how and processes to leverage PlasmidFactory’s excellent market position and unrivalled reputation as provider of exceptionally pure materials for gene and cell therapy and to further promote PlasmidFactory’s breakthrough minicircle technology. The founder and major shareholder Dr. Martin Schleef rolls over a substantial portion of his proceeds and will stay on board as PlasmidFactory’s managing director.

DZ BANK AG advised the shareholders of Plasmid Factory in the transaction.


Advised in the sale of

PlasmidFactory GmbH & Co. KG




MidCap Alliance